NCT05440786 2026-04-13
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT04293393 2026-03-12
CARABELA
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04751929 2026-02-20
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02152631 2026-02-06
JUNIPER
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02747004 2026-02-06
Next MONARCH 1
Eli Lilly and Company
Phase 2 Active not recruiting
NCT02763566 2026-02-05
MONARCH plus
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02246621 2026-02-03
MONARCH 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05169567 2026-01-16
postMONARCH
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02107703 2025-10-21
MONARCH 2
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03939897 2025-09-24
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02981940 2025-09-02
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04975308 2025-07-11
EMBER-3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03155997 2025-04-20
monarchE
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03706365 2025-04-20
CYCLONE 2
Eli Lilly and Company
Phase 2/3 Active not recruiting